In the fight against Mexican criminal cartels, social network analysis can predict and map out their alliances and subgroups — using algorithms to predict new connections. In this commentary, Nonresident Scholar in Drug Policy and Mexico Studies Nathan P. Jones and his co-authors outline their recent work in the field.
Nathan P. Jones, Oscar Contreras Velasco, John P. Sullivan, Chris Callaghan, Irina Chindea, Daniel Weisz ArgomedoOctober 18, 2023
Two new bills introduced in the Texas Legislature could jeopardize the care received by Medicaid patients, writes Vivian Ho, the James A. Baker III Institute Chair in Health Economics. She explains why the legislation would weaken county-owned insurance plans and raise Texans’ tax bills.
The first step to reducing methane, Agerton and Gilbert argue, is to directly measure it. Their new Forbes post explains why inventory-based incentives that merely estimate emissions must give way to direct methane monitoring.
Fellow Vivian Ho discusses the sources she's following that shape her thoughts on how long the pandemic will last and what policy actions seem most promising. Baker Institute Blog: https://bit.ly/3aRTDrF
The authors explain why $100 billion allocated by the CARES act to compensate health care providers for unreimbursed expenses and lost revenue from may be woefully inadequate.
Baker Institute health policy experts provide links to some of the sources they found helpful in understanding developments in the coronavirus outbreak.
There is a flood of information about the coronavirus pandemic. In this Baker Institute blog, health policy fellow Vivian Ho provides links to some of the best sources followed by career health policy researchers.
High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
